Clinical Trials Directory

Trials / Completed

CompletedNCT02417844

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fed Conditions

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
Male
Age
18 Years – 64 Years
Healthy volunteers
Accepted

Summary

Two tamsulosin HClformulations will be tested in fed state

Conditions

Interventions

TypeNameDescription
DRUGtamsulosin (Astellas)
DRUGTamsulosin HCL

Timeline

Start date
2015-04-01
Primary completion
2015-05-01
Completion
2015-05-01
First posted
2015-04-16
Last updated
2020-04-17
Results posted
2020-04-17

Source: ClinicalTrials.gov record NCT02417844. Inclusion in this directory is not an endorsement.